These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9152730)

  • 41. The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population.
    Brar JS; Parepally H; Chalasani L; Gopalani A; Appel N; Chengappa KN
    Ann Clin Psychiatry; 2008; 20(3):139-44. PubMed ID: 18633740
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.
    Crespo-Facorro B; Pérez-Iglesias R; Mata I; Ramirez-Bonilla M; Martínez-Garcia O; Pardo-Garcia G; Caseiro O; Pelayo-Terán JM; Vázquez-Barquero JL
    J Psychopharmacol; 2011 Jun; 25(6):744-54. PubMed ID: 21292922
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of extrapyramidal side effects with terguride.
    Filip V; Marsálek M; Hálková E; Karen P
    Psychiatry Res; 1992 Jan; 41(1):9-16. PubMed ID: 1348584
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
    Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
    J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Attenuation of neuroleptic-induced extrapyramidal side effects by Kava special extract WS 1490.
    Boerner RJ; Klement S
    Wien Med Wochenschr; 2004 Nov; 154(21-22):508-10. PubMed ID: 15638068
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication.
    Glazer WM; Morgenstern H; Schooler N; Berkman CS; Moore DC
    Br J Psychiatry; 1990 Oct; 157():585-92. PubMed ID: 1983390
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of tardive dyskinesia with donepezil: a pilot study.
    Caroff SN; Campbell EC; Havey J; Sullivan KA; Mann SC; Gallop R
    J Clin Psychiatry; 2001 Oct; 62(10):772-5. PubMed ID: 11816865
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Motor disturbances in psychosis].
    Putzhammer A; Hajak G
    Psychiatr Prax; 2005 Apr; 32 Suppl 1():S1-2. PubMed ID: 15818514
    [No Abstract]   [Full Text] [Related]  

  • 49. Neuroleptic malignant syndrome with risperidone.
    Levin GM; Lazowick AL; Powell HS
    J Clin Psychopharmacol; 1996 Apr; 16(2):192-3. PubMed ID: 8690838
    [No Abstract]   [Full Text] [Related]  

  • 50. [Torticollis spasmodicus as a manifestation of tardive dystonia].
    Silberbauer C; Rittmannsberger H
    Fortschr Neurol Psychiatr; 1995 Oct; 63(10):388-92. PubMed ID: 8529987
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pisa syndrome-like peculiar posture occurred while running was successfully improved with risperidone.
    Harada K; Saito T
    Psychiatry Clin Neurosci; 2006 Dec; 60(6):771-2. PubMed ID: 17109715
    [No Abstract]   [Full Text] [Related]  

  • 52. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
    Fleischhacker WW; Eerdekens M; Karcher K; Remington G; Llorca PM; Chrzanowski W; Martin S; Gefvert O
    J Clin Psychiatry; 2003 Oct; 64(10):1250-7. PubMed ID: 14658976
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Neurotoxicity related to lithium-risperidon combination treatment in a patient with schizoaffective disorder].
    Böker H; Brandenberger M; Schopper C
    Psychiatr Prax; 2007 Jan; 34(1):38-41. PubMed ID: 17106843
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Buspirone in the treatment of tardive dyskinesia.
    Moss LE; Neppe VM; Drevets WC
    J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tardive dyskinesia presenting as a psychosis.
    Asnis GM; Nathan RS; Davies SO; Halbreich U
    J Nerv Ment Dis; 1979 Dec; 167(12):762-3. PubMed ID: 41884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risperidone-induced tardive dyskinesia.
    Saran BM
    J Clin Psychiatry; 1998 Jan; 59(1):29-30. PubMed ID: 9491064
    [No Abstract]   [Full Text] [Related]  

  • 60. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
    Feldman PD; Kaiser CJ; Kennedy JS; Sutton VK; Tran PV; Tollefson GD; Zhang F; Breier A
    J Clin Psychiatry; 2003 Sep; 64(9):998-1004. PubMed ID: 14628974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.